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Breast cancer transcriptome acquires a myriad of regulation changes, and splicing is critical for the cell to
‘‘tailor-make’’ specific functional transcripts. We systematically revealed splicing signatures of the three
most common types of breast tumors using RNA sequencing: TNBC, non-TNBC and HER2-positive breast
cancer. We discovered subtype specific differentially spliced genes and splice isoforms not previously
recognized in human transcriptome. Further, we showed that exon skip and intron retention are
predominant splice events in breast cancer. In addition, we found that differential expression of primary
transcripts and promoter switching are significantly deregulated in breast cancer compared to normal
breast. We validated the presence of novel hybrid isoforms of critical molecules like CDK4, LARP1, ADD3,
and PHLPP2. Our study provides the first comprehensive portrait of transcriptional and splicing signatures
specific to breast cancer sub-types, as well as previously unknown transcripts that prompt the need for
complete annotation of tissue and disease specific transcriptome.
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T

he process of breast cancer progression is accompanied by genomic alterations including inherited genetic
variations, acquired genomic aberrations, changes in the splicing and transcriptome, and resulting protein
functions1–3. The recent transcriptome profiling studies highlighted the diversity and flexibility of genomic
processes that allow a cancer cell to ‘‘tailor-make’’ specific functional units from the available exons of the gene4–7.
The process of generating novel cancer-specific isoforms is driven by alterations at several layers such as alternative pre-RNAs, promoter usage, and splicing and polyadenylation that alters coding regions and consequently,
the function of the resulting proteins8–10. Therefore, understanding these regulatory elements is essential for a
complete appreciation of the genomic contribution to the pathobiology of breast cancer. The relevance of
differential splicing in human cancer is an evolving area of cancer biology. The complete annotation of all the
transcripts associated with each cancer relevant gene in the human genome is still far from complete11–13.
Consequently, distinguishing the isoforms that are generated due to natural transcriptomic dynamics from the
ones that occur because of diseases such as cancer remains a great challenge. In addition, determining tissuespecific splice variants will be equally important for a better understanding of cancer specific splicing of genes14–17.
In breast cancer, Tenascin C (TNC) was one of the first genes identified to comprise an alternatively spliced
region that induces focal adhesion and cell migration in stromal fibroblasts, periductal fibroblasts and residual
myoepithelial cells18,19. Further microarray and qRT-PCR based studies reported genes including CD44, ESR1,
ESR2, CALD1, COL6A3, LRRFIP2, PIK4CB, and TPM1, that produce breast cancer specific splice-variants20.
Interestingly, an overall up-regulation of splicing factors and remarkable changes in the exon models are widely
observed in breast cancer21. Recent studies have identified specific variants of TP53, SYK, BRCA1, and MUC1 in
breast cancer22–27, as well as splice variants of many genes28–31 that play important functional roles in tumor
progression. Although focused studies on differential splicing of specific genes and microarray studies allowed us
to identify many exons that undergo alterations in cancer20–22, the emerging RNA sequencing offers unprecedented approach to discover cancer specific isoforms, global transcriptomic alterations and post-transcriptional
changes on large scale.
Here, we reveal the transcriptomic landscape of TNBC, non-TNBC and HER2-positive breast cancer in
comparison to normal breast samples using massively parallel paired-end RNA sequencing. We determine the
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differentially spliced genes and resulting isoforms, differential promoter usage, and expression of pre-RNA and coding regions between
the normal and cancer breast tissues. More interestingly, breast cancer associated novel splice events, and core sets of novel genes modified at the pre-RNA and splicing levels are also revealed. Together,
this study provides the first comprehensive portrait of pre- and posttranscriptional changes and splicing signatures that are specific to
TNBC, non-TNBC and HER2-positive breast cancers.

Results
Strategy to identify the pre- and post-transcriptional elements
that underlie the transcriptomic diversity. The overview of all the
analysis performed in this study is outlined in Figure 1A. We set out to
define the significance of splicing in breast cancer subtypes using RNAsequencing of TNBC, non-TNBC, HER2-positive breast cancers in
comparison to human breast organoids (epithelium) samples derived
from normal healthy women32 (mentioned throughout the manuscript
as normal breast samples or NBS). The global statistics on the reads
is presented in Supplemental Table 1. The 17 well-characterized
individual human breast cancer tissues include six TNBC, six

non-TNBC, and five HER2-positive breast cancer samples5. The
RNA sequencing of the samples was performed using the Illumina
platform as outlined in our recent study5. We first mapped the reads
to the Ensembl GRCh37.62 B (hg19) reference genome using RNA
sequence aligner Tophat that aligns the reads across splice junctions
independently of gene annotations33.
The reference independent transcript reconstruction was performed using Cufflinks34–36. The isoforms identical to the Ensembl
GRCh37.62 B reference genome (known isoforms) and the ones
that comprise at least one novel splice junction (novel isoforms),
are detected using cuffcompare program37. Once isoforms are isolated from all the assembled transfrags, we employed cuffdiff program to identify the differentially spliced genes between individual
breast cancer subtypes against normal breast samples. Further,
comparative analysis at the level of primary transcripts, promoter
usage, spliced isoforms and coding regions provided a comprehensive overview of the transcriptional and post-transcriptional
elements in breast cancer. To detect the TNBC, non-TNBC and
HER2-positive breast cancer-specific splice events such as exon
skip, exon inclusion, transcript start and termination and intron

Figure 1 | TNBC, non-TNBC and HER2-positive breast cancer RNA sequencing. (A) Overview of the steps involved in the splicing and transcriptional
regulatory elements that are specific to TNBC, non-TNBC and HER2-positive breast cancers in comparison to NBS using de novo assembled
transcripts from RNA sequencing. (B) Total read distribution between NBS and cancer – higher proportion of intergenic reads is found in the cancer
as compared to NBS. (C) Relative distribution of novel, identical to reference, and mapping into the reference transcripts in the four studied groups.
(D) Overlap of the novel isoforms between the three breast cancer subtypes.
SCIENTIFIC REPORTS | 3 : 1689 | DOI: 10.1038/srep01689
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Table 1 | The number of de novo assembled transcripts and genes (above 0.3 FPKM)
Groups
Triple Negative Breast Cancer (TNBC)

Non-Triple Negative Breast Cancer (Non-TNBC)

HER2-positive Breast Cancer

Normal Breast tissue (NBS)

Sample
name

Novel
transcripts

Reference like
transcripts

Novel
genes

Reference
like genes

TNBC1
TNBC 2
TNBC 3
TNBC4
TNBC5
TNBC6
Non-TNBC1
Non-TNBC2
Non-TNBC3
Non-TNBC4
Non-TNBC5
Non-TNBC6
HER2_1
HER2_2
HER2_3
HER2_4
HER2_5
NBS1
NBS2
NBS3

19005
11591
18462
15204
14616
13083
14761
17851
18144
15210
16424
13482
17075
15869
15587
14616
9855
17075
14032
14079

4351
4873
3464
5522
5180
4752
6513
4944
4931
5494
5340
5304
4816
4974
5058
4735
4519
4816
8610
8235

8057
6162
7660
7363
7240
6740
7488
7946
7926
7448
7751
6864
7762
7426
7108
7851
5514
7762
7663
7649

4004
4441
3210
5007
4726
4752
5880
4526
4525
5041
4887
4843
4593
4624
4334
4410
4151
4593
7621
7292

retention, we employed a direct exon model comparison analysis
as well as multivariate analysis38.
De novo assembly of transcripts reveals high ratio of novel
isoforms. The number of the de novo assembled transcripts and
the corresponding genes in each sample and group are presented
in Table 1. Examination of the read distribution and the
reconstructed transcripts revealed several important observations.
First, while about 73% of the NBS reads map into exons, this
percent is only 58% in the breast cancer samples (Figure 1B).
Second, in both cancer and NBS, higher proportion of novel, as
compared to reference isoforms was estimated (Figure 1C). Third,
among the novel isoforms that map within the reference, the breast
cancer groups encompass a high percentage of novel junctions than
the normal breast samples (Figure 1C). Fourth, the majority of the
genes with novel isoforms appear to be identical between TNBC,
non-TNBC and HER2-positive groups (Figure 1D, the referencelike isoforms and the overlap with NBS are shown on
Supplemental Figure 1). Finally, the unsupervised clustering
revealed that the NBS clustered together but distant to the breast
cancer groups as expected (Supplemental Figure 2A and 2B). To
eliminate the partially assembled transcripts and to focus on
defining the splice signature of breast cancer, we restricted our
further analysis to the isoforms that are similar to reference and
novel isoforms with more than two exons.
Identification of the differentially spliced genes in breast cancer.
To identify the differences in splice ratios between the NBS and the
different breast cancer subtypes, we employed Cuffdiff37, which
calculates the changes in the relative splice abundances by
quantifying the square root of the Jensen-Shannon divergence on
all the primary transcripts that produce two or more isoforms
(Supplemental Figure 3). It is essential to note that the distributions
of genes, the primary transcripts, and isoform FPKM are comparable
between the samples that are taken for the differential splicing test
(Supplemental Figures 2–5). When the NBS were compared against
TNBC-subtype, 423 primary transcripts belonging to 377 genes,
generating 496 novel isoforms, were found to be differentially
spliced with the FDR and corrected p-value less than 0.05
(Figure 2A and 2E, Supplemental File 1). Similarly, comparisons of
NBS against non-TNBC and HER2-positive breast cancers allowed us
to identify 270 and 460 primary transcripts belonging to 242 and 387
SCIENTIFIC REPORTS | 3 : 1689 | DOI: 10.1038/srep01689

differentially splicing genes, producing 331 and 550 novel isoforms,
respectively (Figure 2B, 2C and 2E, Supplemental Figure 6,
Supplemental Files 2 and 3). An example of differentially spliced
gene is shown on Figure 2D, illustrating the different SYNE2
isoforms identified in NBS, TNBC, non-TNBC and HER2 positive
samples. We discovered 39 genes (including, TAF2, PRKDC, PGK1,
CHD8, TFAP2A and STK10, Supplemental File 4) that show statistically significant differential splicing in all the three breast cancer
subtypes. When a similar differential splicing test was performed
within the cancer groups, only few genes were differentially spliced
among samples, indicating the similarity among the breast cancer
subtypes and distinctiveness between normal breast and cancer
(Supplemental Figure 7, Supplemental Files 5–7).
Unraveling the splice signatures of TNBC, non-TNBC and HER2positive breast cancers. We next investigated the differentially
spliced (p-value,0.05, FDR,0.05) novel isoforms in the context
of the same transcription start site (TSS) in the breast cancer
subtypes by Jensen-Shannon divergence statistical test. The top 20
exclusively expressed in each cancer subtype isoforms are shown on
Figure 3. These isoforms are sorted based on their preferential
expression in one of the cancer subtypes versus very low or absent
in the other two; all these transcripts were not detected in NBS. The
distribution of the differentially spliced transcripts for the three
cancer types is shown on Supplemental Figure 8; from them, 322,
246 and 368 isoforms are almost exclusively expressed in TNBC,
non-TNBC and HER2-positive breast cancer samples, respectively,
and are not present in NBS (Supplemental Files 8–10). The majority
of these cancer subtype specific isoforms comprise novel junctions
and thus represent novel isoforms that have not been reported before
(Supplemental Figure 8 shows the top twenty highly abundant
isoforms that are not expressed in NBS, and Supplemental File 11
(GTF) shows the exon models). The isoforms expressed exclusively
in a cancer subtype, and not present at all (FPKM 5 0) in the other
subtypes are presented in Supplemental Files 12–14.
Other cancer specific isoforms included genes critical for cellular
functions such as MTOR and MSI2 in the TNBC group, ZMYND19
and SEPT8 in non-TNBC, and PRKDC and DIM1 in HER2-positive
group (see Supplemental Files 8–10). We further evaluated whether
the identified cancer specific isoforms comprise a functional open
reading frame (ORF) by aligning the RNA of the novel isoforms
against the human ORFeome 8.1 (http://horfdb.dfci.harvard.edu/).
3
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Figure 2 | Differentially spliced genes and their associated isoforms between NBS and TNBC, non-TNBC and HER2-positive breast cancers.
(A-C) Circos plots representing the statistically significant, differentially spliced genes identified through pairwise comparisons of TNBC vs. NBS (A),
non-TNBC vs. NBS (B), and HER2-positive vs. NBS (C). The genes shown as dots are coloured based on their Jensen-Shannon divergence test q value.
The stacked histograms represent the abundance (FPKM) of specific differentially spliced isoforms that results from the primary transcripts. (D) Close
view of chromosome 6 segment of TNBC vs. NBS comparison of differentially splicing genes, exemplified through SYNE1 novel splice variant expression
dynamics shown as a line graph. Tcon numbers indicate the reassembled, distinct novel exon models of SYNE1. (E) Statistically significant differentially
splicing genes and their associated isoforms – comparison with NBT.
SCIENTIFIC REPORTS | 3 : 1689 | DOI: 10.1038/srep01689
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Figure 3 | TNBC, non-TNBC and HER2-positive breast cancers specific isoforms. Heat map showing the top twenty novel junctions differentially
expressed isoforms among the three cancer subtypes. Red color indicates high expression levels, and green color indicates low expression levels. The top
twenty are selected based on their abundance (FPKM values shown on the heat map) in TNBC (A), non-TNBC (B) and HER2-positive (C). The gene
names are shown on the right and the closest emsembl transcript identifier is presented on the left of each heat map.

Notably, 18% (TNBC), 23% (non-TNBC) and 17% (HER2-positive)
of the novel isoforms appear to comprise a fully functional open
reading frame (Supplemental Table 2) revealing the possibility of
expressed novel cancer specific proteins.
To experimentally validate the differential expression of the novel
subtype specific isoforms, we selected novel isoforms exclusively
expressed in each cancer group: EIF4EBP1 and MRPS15 for
TNBC; NDUFA, PBX1 and MUTS1 for non-TNBC, and AZIN,
VAMP5, and ATP5G1 for HER2-positive group. Primers that bind
to unique regions of these isoforms were designed (Supplemental File
15) and the qRT-PCR analysis and sequencing of the products was
carried out. The expression levels detected by qRT-PCR were similar
to the ones revealed through transcriptome sequencing and were
higher in the cancer samples compared to low or absent in the
NBS (Figure 4).

Significance of the primary transcript abundances in generation
of cancer sub-type specific isoforms. Aberrant splicing and cancer
specific splice variants represent emerging cancer biomarkers39,40.
However, the fine-tuning of splicing cascade occurs at the level of
primary transcript and promoter selection. Although the RNA
sequencing of normal and cancer breast tissue captures the snap
shot of a post-transcriptional state, the number and abundance of
primary transcripts associated with a given gene can be derived from
the sum of the abundances of the transcripts that share the same TSS.
The changes in the relative abundance of the TSSs between NBS and
TNBC, non-TNBC and HER2-positive breast cancers provides a list
of cancer subtype-specific cellular choices at transcription regulation
level (Figure 5A).
All reconstructed genes comprised two or more isoforms and more
than 50% (TNBC: 11394, non-TNBC: 7107, HER2-positive: 8300

Figure 4 | Quantitative real time PCR (qRT-PCR) experimental validation of differential expression of cancer subtype specific isoforms as compared to
NBS: (A) TNBC, (B) Non-TNBC, and (C) HER2 positive. A good correlation between RNA-sequencing and qRT-PCR data is observed.
SCIENTIFIC REPORTS | 3 : 1689 | DOI: 10.1038/srep01689
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Figure 5 | Identification of differential primary transcripts, promoter usage and promoter switch in breast cancers. (A) The volcano plots show
the statistically significant primary transcripts (in blue, corrected p , 0.05 and FDR , 0.05), identified in the comparisons of TNBC vs. NBS, non-TNBC
vs. NBS, and HER2-positive vs. NBS pair wise comparisons using cuffdiff program. (B) The relative abundance of all the primary transcripts
associated with TFAP2A, a gene that is involved in differential promoter usage in TNBC, non-TNBC and HER2-positive breast cancers. All the primary
transcripts (TSSs) of TFAP2A and their abundances are shown. The primary transcripts (TSS) that produce isoforms identical to a known ensembl
transcript are shown in different colour other than black. The novel isoforms that share at least one splice junction with ENST00000489805 isoform of
TFAP2A are shown in black.

genes) qualified for the two-tailed t-test in Cuffdiff. To eliminate the
primary transcripts that arise due to impartial built, the transcripts that
comprised at least 5–8 exons and were similar to the reference were
included in these analyses. The differential expression analysis in the
TNBC group revealed 1219 up- and 159 down-regulated TSS groups as
compared to NBS (Supplemental File 16). In the non-TNBC group,
650 and 355 TSS groups were up and down-regulated, respectively, and
1333 and 211 TSS groups were up- and down-regulated in the HER2positive samples (Supplemental File 17 and 18). There were 161 genes
deregulated in all three types of breast cancer at the primary transcript
level (Supplemental File 19). In comparison to differential splicing, the
number of genes regulated through differential primary transcript
expression appears to be higher. Therefore, the primary transcript
expression appears to be a prevalent mechanism contributing to the
isoform diversity in cancer. Several important gene groups, encoding
transcription factors, histone modifiers, protein kinases and receptors,
are found to be deregulated in all the three comparisons.
Differential promoter usage and promoter switch. We next investigated the differential promoter usage by grouping the primary
transcripts of a gene based on the promoter used. This was followed by testing changes in the isoform abundance by measuring
the square root of the Jensen-Shannon divergence that occur within
and between these groups in normal and cancer breast samples.
There were 138, 83 and 178 distinct promoter switching genes in
TNBC, non-TNBC and HER2-positive groups, respectively, as
compared to NBS (Supplemental Table 3, Supplemental Files
20–22). Interestingly, only five genes (HSPA8, MTAP, CTDP1,
TFAP2A and DTX4) that employ distinct promoters were shared
among the three cancer groups (Supplemental Figure 9).
We next investigated the potential promoter switch regulation for
the genes comprised from more than one transcript initiating from
distinct genomic loci. Initially, we separated the novel and the known
isoforms associated with genes that utilize distinct promoters, then
identified the isoforms with altered coding sequence due to promoter
switch. There were 75, 44 and 152 coding region-altered transcripts
resulting from promoter switch events in TNBC, non-TNBC and
HER2-positive breast cancer subtypes, respectively (Supplemental
Table 3, Supplemental File 23–25).
For selected genes, the promoter switch and the posttranscriptional splice regulation was investigated in details at the level of the
individual gene. In many cases, we observed multiple transcripts with
functional ORFs resulting from the same primary transcript. An
example is transcription factor AP-2-alpha (TFAP2A). We identified
12 distinct primary transcripts (TSS I – TSS XII) that produced 20
SCIENTIFIC REPORTS | 3 : 1689 | DOI: 10.1038/srep01689

different TFAP2A isoforms, including five known (Figure 5B).
Among them, only twelve isoforms encoded fully functional ORFs
(potential protein product). Twelve novel isoforms were found in
TNBC group, and four TSSs (TSS I, TSS II, TSS VII and TSS XI)
appear to encode the predominant species in TNBC group. Although
similar isoforms were seen in the NBS, they differed in their expression levels and coding sequences (Supplemental Figure 10). The combined expression of different transcripts originating from the same
TSS differed significantly between TNBC and NBS. Our data show
that TFAP2A expression differences between TNBC and NBS result
from differences in the pre-mRNA amounts, differential promoter
usage, as well as differential regulation at post transcriptional level
(i.e. splicing). Apart from TFAP2A, several other candidates that
employ promoter switching to produce cancer specific isoforms were
identified (Supplemental File 26).
Pathways influenced by deregulated genes in breast cancer. To
determine the impact of all the above described transcriptomic
modifications on biological functions and pathways, we performed
Ingenuity Pathway Analysis (IPA) (Supplemental Figures 11–13). In
TNBC, the pathways most severely deregulated at the level of
differential promoter usage and promoter switch included cellto-cell signaling and interaction, cellular movement, cellular development, system development and immunological response (Supplemental File 27). In contrast, when the posttranscriptional splice
deregulation was examined (differential expression of isoforms
resulting from the same TSS), genes from cell death, cell cycle pathway, and cellular function and maintenance were predominant.
Similar analysis for the non-TNBC and HER2-positive groups
revealed cell-to-cell signaling and interaction as one of the main
pathways deregulated at transcriptional level in all three breast
cancer subtypes; whereas the posttranscriptional splice deregulation affected mostly cell death, cell morphology, and posttranslational modifications pathways (Supplemental File 28 and 29).
Finally, the investigation of whether there is a core set of genes that
are consistently and significantly deregulated in their primary transcript abundances, promoter usage/switching and post-transcriptional splicing, outlined fourteen genes in TNBC including
DYRK1A, MSI2, MLL5, ABCG1, and PHF16 (Supplemental Figure
14A, Supplemental File 30). Similarly, we found FGD4, NCAPD2,
KIAA0664, TIAA1217 and SNHG7 to be significantly deregulated at
the level of primary transcript, promoter usage and splicing in the
non-TNBC subtype (Supplemental Figure 14B, Supplemental File
31). In the case of HER2-positive, 26 such core genes are found
6
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Figure 6 | Annotation of novel splice events. (A) Peaks graph showing the inclusion or exclusion of exons that occur in the individual breast cancer
subtypes in comparison to NBS. The exact inclusion or exclusion event count is shown on the relevant peak. (B) An example of ‘‘switch like’’ exon
occurrence in XBP1, encoding potent transcription factor. In normal breast samples sample, the junctions and reads support the possibility of two types of
isoforms that include or exclude exon 2 in XBP1. In contrast, in all six non-TNBC breast cancer type, the reads encode the entire five exons, supporting
only the potent DNA binding domain intact splice variant expression.

and they include DICER1, CASP10, SORL1, PPP1R12A, INPP4B and
ATP11B (Supplemental Figure 14C, Supplemental File 32).
Exon skipping and intron retention are predominant breast
cancer specific splicing events. Almost 90% of multi-exon human
genes undergo alternative splicing during development, cell differentiation, and disease4,41. The alternative exon selection manifests
between subtle and ‘‘all or nothing’’ mechanisms of specific exons
expression. We compared the splice profiles of the 17 breast cancer
samples individually against normal breast samples, as well as
merged breast cancer subtypes against merged normal breast
samples. Events of exon skipping, mutually exclusive exon,
alternative start, stop and intron retention, as compared to NBS,
were annotated using a multivariate analysis of transcript splicing
program, MATS38 (Figure 6A, Supplemental Table 4–6). MATS
provides a statistical framework that determines the junction
counts supporting the inclusion or the exclusion of specific splice
SCIENTIFIC REPORTS | 3 : 1689 | DOI: 10.1038/srep01689

events in cancer against NBS. In the TNBC group, we identified 2898
and 2038 exon skipping and intron retention events, respectively. In
TNBC, 1549 mutually exclusive exons, 446 transcripts start and 443
transcript stop site changes were observed. Intron retention and exon
skipping appear to be the most predominant splice events in all three
breast cancer subtypes. The complete annotation of splice events that
are specific to TNBC, non-TNBC and HER-positive group is
presented in Supplemental File 33 to 35.
The inclusion of exon and intron in cancer appears to be the
predominant splice event in all three types of breast cancer
(Figure 6A, Supplemental Files 36–38). Among breast cancer specific
events that occur in all the samples of the subgroups, we often
observed events such as switch-like exon, defined by the absence of
reads supporting one of the compared conditions. For example, we
detected reads supporting two exon models of XBP1, a key transcription factor with a critical role in anti-estrogen responsiveness in
breast cancer cells: inclusion of all intact exons from the genome
7
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reference, thus encoding a whole length functional protein, and
alternative isoform that is lacking exon 2. Exon 2 is not in frame
and its elimination leads to a premature stop codon generation early
in the newly formed isoform, likely subjected to a Nonsense mediated
mRNA decay (NMD). This exon 2 excluding isoform appears to be
expressed in NBS, but in none of the six non-TNBC samples
(Figure 6B). Another interesting observation on XBP1 is higher prevalence of the spliced isoform XBPs that is related to endoplasmic
reticulum (ER) stress and unfolded protein response (UPR) in the
breast cancer samples compared to the NBS. Of note, although this
prevalence was observed in all three breast cancer groups, the greatest
abundance of XBP1s was seen in the non-TNBC group.
Similar to XBP1 exclusive exon presence in cancer vs NBS is seen
for other genes, such as breast cancer anti-estrogen resistance 1
(BCAR1), exon 6, and high mobility group nucleosome-binding
domain-containing protein 3 (HMGN3), exon 6. In the later two
examples however, in contrast to XBP1, the exclusion of the exon
does not lead to NMD. In both cases, a suggested mechanism of
action is through overexpression in the cancer cells of functional
protein, which is suppressed in the NBS through a mechanism of
exon exclusion. Finally, to supply confidence in the MATS outcomes,
we cross-compared them with the direct exon models generated by
cufflinks and cuffcompare – the majority of the novel splice events
detected by MATS were reflected in the cufflinks output.
Another interesting finding revealed by combined application of
MATS and direct exon modeling is the formation of novel isoforms
with new exon assembly. We observed such novel isoforms in several
genes, including Cyclin-dependent kinase 4 (CDK4), La-related protein 1 (LARP1), PH domain leucine-rich repeat-containing protein
phosphatase 2 (PHLPP2), and Gamma-adducin (ADD3) in all the
cancer samples of a subtype (Supplemental Figures 15 and 16). To
experimentally validate the assembly and expression of the novel
isoforms, we designed unique primers and performed RT-PCR and
subsequent sequencing analysis. We were able to identify the
expected hybrid exon assembly in the corresponding breast cancer
samples, thus validating the RNA-seq findings and increasing the
confidence of the analysis (Figure 7A–7C).
For all three genes listed above, the novel hybrid isoforms contained exon combinations of two or more known isoforms. For
instance, the newly identified isoform of CDK4 includes the first exon
of ENST00000547853, which is added as a first exon to the
ENST00000257904, comprising seven exons through a novel junction, and skipping an exon located in the 5 prime untranslated region
from ENST0000257904. Of note, the skipped exon is known to be
involved in the translation of CDK4 by p53 and TGFbeta42,43. It is also
notable that the RNA-seq analysis revealed this exon model in three
of the six non-TNBC samples, predominantly expressed in all three
of them. The Sanger validation confirmed the presence of the novel
CDK4 isoform in all three RNA-seq positive samples, and in one
additional non-TNBC sample, thus confirming the prevalence
expression in the non-TNBC group (four out of six, see Figure 7A).
Similarly, a novel hybrid isoform was identified for LARP1
(Figure 7B, Supplemental Figure 16). LARP1 is an RNA-binding
protein that regulates negatively RAS-MAPK pathway and is shown
to be involved in cell division, migration and apoptosis44,45. The
human LARP1 gene has 15 different isoforms, from which only
one - ENST00000336314 – is known to be expressed at protein level.
The N-terminal region of the novel LARP1 isoform discovered in our
study retains the exon model of ENST00000336314 except the first
exon. That first exon appears to be similar to the first exon of another
isoform, ENST00000518297, and encodes 145 (as compared to 68
encoded by the first exon of ENST00000336314) amino acids of the
N-terminal region, proximal to the RNA binding domain (AA397487). RT-PCR and Sanger sequencing confirmed the presence of the
novel hybrid isoforms in four out of the 6 non-TNBC samples in
which it was originally detected by RNA-seq. Similarly, novel hybrid
SCIENTIFIC REPORTS | 3 : 1689 | DOI: 10.1038/srep01689

isoforms, including altered UTRs, were identified and confirmed by
Sanger sequencing for the tumor suppressor PHLPP246 (Figure 7C,
Supplemental Figures 15 and 16) and the membrane skeletal associated protein ADD3 (Supplemental Figures 15 and 16)47.
In addition to the studied breast cancer samples, we screened for
the presence of these ‘‘novel hybrid isoforms’’ in several breast cancer
cell lines including ZR75, MCF-7, SKBR3, SUM159, BT549 and
HS578T (Figure 7D) in an attempt to identify a reproducible model
system for further biological characterization of the novel isoforms.
Of note, the novel hybrid isoform of CDK4 was present in all the cell
lines whereas ADD3 and LARP1 were detected only in MCF7 cell
line. The hybrid PHLPP2 isoform was detected in MCF7 and
HS578T cell lines.
Finally, we compared the exon assembly of all the assembled transcripts without including a statistical cutoff or overlapping with
MATS output, and outlined the exons that are under cancer-specific
splice control (Supplemental Tables 7 and 8, Supplemental Files 39–
41). This allowed us to inspect and report all the cancer-related splice
changes in TNBC, non-TNBC and HER2-positive breast cancers.
We next set to confirm the expression of the novel hybrid isoforms
of LARP1 and PHLPP2 on protein level (Supplemental Figure 15). For
LARP1, the hybrid protein isoform is estimated to be 1096AA long (as
compared to the 1019AA of the closest isoforms ENST00000336314).
As expected, a band corresponding to ENST00000336314 was detected
by Western blot in all three tested breasted cell lines (MCF7, ZR-75 and
HS578T, Figure 7E). In MCF-7, one additional band, corresponding to
the longer hybrid LARP1 isoform was present. As noted above, MCF7
was the only cell line expressing the LARP1 hybrid cDNA; thus,
Western blot completely agreed with the RT-PCR and RNA sequencing data.
According to our RNA-seq findings, PHLPP2 hybrid isoform is
expected to encode a protein of 1256AA (as compared to the 1323AA
of the closest isoform ENST00000568954). Concurring with the RTPCR results, bands corresponding to both ENST00000568954 and
the shorter novel hybrid isoform were detected in MCF-7 and
HS578T cell lines by Western Blot; none of these bands was present
in the ZR-75 (Figure 7F). In MCF-7, one additional longer band was
detected by our Western blot. We could not identify reads corresponding to such an elongated PHLPP2 isoform among the TNBC,
non-TNBC and HER-2-positive samples; thus, the detected longer
protein might potentially represent MCF-7 specific isoform. Of note,
the only PHLPP2 isoform known to be expressed at protein level so
far was ENST00000568954.

Discussion
Stringently regulated mechanisms such as transcription, splicing,
poly-adenylation, RNA editing, post-translational modification
and proteolysis enable the generation of multiple functional variants
of an individual gene. In cancer, many of these mechanisms are
seized to favor the malignant state. Massive parallel RNA sequencing
analysis allows us to explore the cancer-related changes that occur at
the stage of transcription, pre-RNA, splicing and editing and to
outline isoforms that are specific for given cancer subtype. Cancer
specific splice variants of genes that control the cell proliferation and
DNA damage (e.g. FGFR2, BRCA1, FHIT), adhesion, invasion
(CD44, MST1R), angiogenesis (VEGF) and apoptosis (BCL10,
CASP2) have been reported in the last decade39. Therapeutic
approaches that target these specific variants are proving to be effective in the clinic. For instance, specific antibody against a domain
coded by exon 6 of a specific splice isoform, CD44v6 is used in
radiotherapy, highlighting the urgent need to explore other promising target niches for cancer treatment31.
Here, for the first time, we provide an overview on all transcriptomic and splicing changes in TNBC, non-TNBC and HER2-positive
breast cancers in comparison to NBS using RNA sequencing analysis.
RNA sequencing is a powerful tool that allows deciphering of
8
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Figure 7 | Validation of novel cancer specific isoforms at cDNA and protein level. (A) CDK4 novel isoform identified in non-TNBC validated by RTPCR. The left side panel shows the relative abundance of all the primary transcripts. The red arrow points to a pie chart that shows the relative abundance
of all the isoforms that originate from the TSS129057. The lower bar chart shows the relative abundance of isoforms that are generated from the TSSs
shown in the middle panel. To indicate the origin of the isoforms, the bars are color coded similar to their primary transcript color. The right side panel
shows a novel isoform that is formed through a junction merging two CDK4 isoforms, ENST00000257904 and ENST00000552862, and skipping the first
non-coding exon of ENST00000257904. The novel isoform does not change coding sequence. The RT-PCR gel electrophoresis is shown on the right. (B)
LARP1 novel isoform identified in non-TNBC samples by RNA sequencing and validated by RT-PCR (gel on the right, the box indicates the region that
was amplified by RT-PCR). (C) PHLPP2 novel isoform identified in TNBC samples by RNA sequencing and validated by RT-PCR (gel on the right, the
box indicates the region that was amplified by RT-PCR). (D) Validation of novel isoforms identified in cancer samples in breast cancer cell lines. LARP1
RT-PCR product was detected in MCF7 only, and PHLPP2 was detected in MCF7 and HS578T; in contrast the CDK novel isoform was detected in all
eight screened cell lines. (E) LARP1 novel protein isoform validation by Western blot analysis in breast cancer cell lines. An additional band,
corresponding to the predicted novel isoform of 1096AA (as compared to 1019 in the wild type) is identified by LARP1 specific antibody. Congruent with
RT-PCR results, the novel longer LARP1 isoform was detected in MCF-7 and not in the remaining tested breast cancer cell lines. (F) PHLPP2 novel
protein isoform validation by Western blot analysis in breast cancer cell lines. The novel shorter (1256AA) as compared to the wild type (1323AA) isoform
was identified in MCF7 and HS578T cell lines, in line with RT-PCR results.
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multiple layers of transcriptome regulation, including promoter selection, transcription, splicing and RNA editing. The notion of breast
cancer specific exons and splice variants of one gene is recent and
most of the studies so far are either focused on individual genes or
utilize preselected splice-sensitive exon expression arrays28,48–51. When
we compared the differentially spliced genes identified by our
unbiased global RNA sequencing approach, followed by reference
independent assembly, we validated many previously reported breast
cancer specific alternatively spliced genes such as FGFR2, NOTCH3,
SYNE2, TLK1 and UTRN (Supplemental Files 42–48)39,45–48.
At the moment of our analysis, no parallel exon array data targeting the cancer subtypes chosen by our study was available in the
Gene expression Omnibus database; however we found a dataset
(GSE33692, Affymetrix Human Exon 1.0 ST Array) that includes
three normal breast samples, nine ductal carcinoma in situ (DCIS)
and 10 invasive breast cancer patient tissue52. The overlap between
the RNA sequencing based alternatively spliced genes and the genes
identified from the comparative analysis of normal vs. DCIS or IBS
are 33.4% and 36%, respectively (Supplemental Figure 17), revealing
breast cancer associated differentially spliced genes regardless of the
specific cancer subtype (Supplemental Files 49 and 50).
Notably, we found significant overlap with a comparative exon
array study on splicing changes between TNBC and HER2-positive
subtypes in comparison to normal tissue. In the exon array study,
3283 and 1976 exons were found to be over-expressed in TNBC and
HER2 positive breast cancer compared to normal breast samples,
respectively48. Among those, 560 genes in the TNBC group and
333 in the HER2-positive group were found to undergo mutually
exclusive and exon inclusion events by our study (Supplemental
Files 42). These findings clearly validate the overlapping gene sets,
but also underlie the strength of the RNA-seq approach allowing
unbiased identification of not only exon-altering changes, but also
novel splicing events such as hybrid isoforms, intron retention, and
partial exon inclusion, that could not be identified through array
technologies. Thus, this study for the first time provides a portrait
of all the novel isoforms specific to TNBC, non-TNBC and HER2positive breast cancers. The vast majority of the identified novel
isoforms that comprise an ORF are predicted to be degraded through
NMD due to the generation of an early stop codon located upstream
of the last exon. However, approximately 5% of these ORF comprising novel transcripts contain all the attributes of a functional ORF,
including properly located polyadenylation signal, and thus may
encode novel expressed protein isoforms – we have validated such
novel, alternative size proteins for LARP1 and PHLPP2.
The comparison of our alternative splicing gene set against previously reported breast cancer cell lines28 (Supplemental Files 44) and
mouse primary tumors with different metastatic capabilities49,50 indicated overlapping alternative spliced genes (Supplemental Files 4546). This is not surprising since, in contrast to the global RNAsequencing approach, these exon array studies include preselected
probe sets and comprise only limited number of genes.
Apart from outlining numerous specific targets for individual focused
studies, our results suggested several previously unacknowledged
expression-regulation mechanisms. Notable example is the ‘‘exonswitch like’’ mechanism (e.g. XBP1), which leads to elevated expression
of fully functional wild type protein in the cancer samples compared to
some proportion of alternative/degraded protein in the normal tissues.
The expression pattern of some of these proteins (XBP1, BCAR1) is
correlated with the invasiveness or the level of malignancy of different
breast tumors. Thus, the observed cancer specific ‘‘exon-switch like’’
may represent alternative mechanism for expressional up-regulation
that may account for their cancer-associated elevated levels. Another
notable example is promoter switching. Promoter switching is a transcription regulatory mechanism that is still not completely defined, but
its significance is increasingly acknowledged. For instance, the expression of breast and small cell lung cancer specific RNA aromatase
SCIENTIFIC REPORTS | 3 : 1689 | DOI: 10.1038/srep01689

(CYP19) splice variant is recently reported to be regulated through
promoter switching and it is proposed to be a therapeutic intervention
point53,54. Our datasets highlighted multiple genes that are regulated
through differential promoter usage or promoter switch in a cancer
subtype specific manner. Further investigation is required to forward
these discoveries into clinical use.
The average number of exons per transcript in our de novo assembly was between eight and ten and did not differ from the current
estimations on the human transcriptome. However, most of the
identified breast cancer specific isoforms were combinations of previously unknown exon assembly, suggesting that our study reveals
largely unknown transcriptomic landscape. It is essential to keep in
mind that the transcriptional and splicing dynamics of various tissues, including the breast, are still being annotated. Therefore, translating our results into clinical use would require validation of the
cancer specific isoforms on a large scale, and detailed annotation of
tissue-specific transcriptomic variability.

Methods
Human patient samples. Dr. Suzanne Fuqua (Baylor College of Medicine) provided
the human breast cancer tissue RNA samples. Dr. Kornelia Polyak (Dana-Farber
Cancer Institute and Harvard Medical School) provided the human breast organoids
(epithelium) samples (NBS). All of the human samples were used in accordance with
the IRB procedures of Baylor College of Medicine and Dana-Farber Cancer Institute
and Harvard Medical School, respectively. The breast tumor types, TNBC, Non-TNBC
and HER2-positive, were classified on the basis of RNA sequencing FPKM abundance5
and immunohistochemical and RT-qRT-PCR classification (data not shown).
Illumina Genome sequencing RNA sequencing library preparation. Large and
small ribosomal RNA (rRNA) was removed from total RNA using RiboMinus
Eukaryote Kit (Invitrogen, Carlsbad, CA). Five micrograms of total RNA were
hybridized to rRNA-specific biotin labeled probes at 70uC for 5 minutes. The rRNAprobe complexes were then removed by streptavidin-coated magnetic beads. The
rRNA-free transcriptome RNA was concentrated by ethanol precipitation. The
cDNA synthesis and DNA library construction for all the seventeen samples were
performed as described5.
Read alignment and transcript assembly. The paired end raw reads were aligned
using the TopHat version 1.2.0 that allows two mismatches in the alignment. The
aligned reads were assembled into transcripts using cufflinks version 2.0.0. The
alignment quality and distribution of the reads were estimated using SAM tools. From
the aligned reads, the de novo transcript assembly was performed to capture the major
splice rearrangements and novel variations that occur in the transcriptomes of TNBC,
Non-TNBC and HER2- positive breast cancers in comparison to NBS using cufflinks
version 1.3.036. In addition, Advanced Reference Annotation Based Transcript
(RABT) Assembly was also performed to check whether including faux reads would
enhance our chances of novel isoform discovery. The cuffcompare program was used
to identify transcripts that are identical to the reference human genome (the Ensembl
GRCh37.62 B (hg19) reference genome). Further analysis and novel isoform call was
performed through the reconstructed transfrags that comprise novel splice junctions
and share at least one splice junction with a reference transcript. The very low
abundant transcripts were identified by binning the transcripts according to their
FPKM and the transcripts with FPKM below 0.3 were eliminated from further
analysis. All the analyses presented in this manuscript are performed using only two
categories of transcripts: transcripts that are identical to reference and transcripts that
comprise novel junctions. The global statistics, which includes the distributions of
FPKM scores across samples and the dendogram that shows the relationship between
the samples based on the reconstructed transcripts, were analyzed using
cummeRbund package of cufflinks suite of programs. The average exon number was
in the reassembled transcripts is comparable to the human genome reference average.
Discovery of differential splicing, primary transcript and promoter usage. The
transcripts that are similar to the reference and the novel splice junctions were chosen
to identify the genes that undergo statistically significant differential splicing between
each breast cancer subtype as opposed to NBS using the most recent cuffdiff program
that allows us to test several samples as a group. Although the manual inspection and
binning of the transcripts based on their abundances emphasizes the heterogeneity in
the expression abundances, it is difficult to predict the significance of it due to the lack
of read depth and complete coverage across the transcripts. Therefore, the samples
that belong to TNBC, Non-TNBC and HER2-positive cancers were given as a group
against the three normal breast samples group for the cuffdiff analysis (p-values and
FDR below 0.05) that reports statistically significant differential splicing, primary
transcripts and promoter usage. In addition, the genes that undergo promoter
switching are also examined for differentially expressing promoters by investigating
the genes that comprise isoforms with distinct transcript start sites.
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Annotation of Novel Splice events. In order to annotate all the novel splice events
that occur in TNBC, Non-TNBC and HER2-positive cancers in comparison to NBS,
we used recently releases program Multivariate Analysis of Transcript Splicing
(MATS)38. Additionally, for consistency checking and independent validation we
used an in-house built program (http://genomics.jhu.edu/software/ASproFile/) to
compare the exon models between isoforms assembled with the program cufflinks for
the normal and cancer samples (as mentioned earlier, only the isoforms that are
similar to reference and isoforms that comprise novel splice junctions were
considered), and determine the splicing differences indicative of exon inclusion,
exclusion, alternative 59, 39, and intron retention events.
GO and IPA analysis. To associate cellular functions with the set of differential
splicing, pre-RNA expression, promoter switching and genes, we used Database for
Annotation, Visualization and Integrated Discovery (DAVID http://
david.abcc.ncifcrf.gov/) and ingenuity pathway analysis (IPA, IngenuityH Systems,
www.ingenuity.com).
RT-PCR validation. Initially, the isoforms associated with the statistically significant
differential spliced genes were identified. Isoforms for individual validation were selected
among the ones expressed only in TNBC, non-TNBC and HER2-positive in
comparison with normal breast samples. It is important to note that these isoforms are
detected in other breast cancer types and absent only in NBS. Primers were designed to
amplify the whole transcripts using unique for the isoform regions. A second set of
validation candidates were chosen from the list of novel isoforms that are discovered
through the novel splice event annotations. When we inspected the exon model of the
isoforms that undergo exon skipping or inclusion in breast cancer compared to NBS, we
detected several new isoforms comprising novel junctions that combine partial exon
models of two distinct isoforms of the same gene. We selected these ‘‘novel hybrid
isoforms’’ and designed unique primers that would amplify only this particular newly
discovered isoforms using qRT-PCR. The amplified products were then gel purified and
sequenced using Sanger’s sequencing. Similar experimental validation was performed
using the same primers in various breast cancer cell lines.
For qRT-PCR, total RNA was isolated using RNeasy Midi kit (Qiagen, Cat No #
75144) and cDNA was synthesized with SuperScript II reverse transcriptase
(Invitrogen) using 1 mg of total RNA and oligo dT primer. qRT-PCR was performed
with the gene-specific primers listed in Supplemental File 15, using a CRX96 Real
Time System (BioRad), Hercules, CA. The levels of RNA expression of all the genes
were normalized against the expression levels of cyclophillin B RNA.
Immunoblot analysis. For the Western Blot Analysis, MCF-7, ZR-75 and HS578T
cells were washed three times with PBS and incubated in a lysis buffer (50 mmol/L
Tris-HCl [pH 7.5], 120 mmol/L NaCl, 1% Triton X-100, 1X protease inhibitor
mixture (Roche), 1 mmol/L sodium vanadate on ice for 30 min. Cell lysates
containing equal amounts of protein were resolved on 14% SDS-PAGE, and
transferred to nitrocellulose membranes. Antibodies for LARP1 and PHLPP2 were
purchased from Santa Cruz Biotechnology (Cat## SC-102006, SC-137663).
Membranes were probed with respective antibodies and detected by means of
enhanced chemiluminescence.
Comparing the RNA sequencing and microarray based differentially splicing
genes associated with breast cancer. To compare the results of splicing analysis our
RNA-sequencing data with published microarray data, we searched for datasets
(datasets that used Affymetrix Human Exon 1.0 ST Array, GPL5175 platform in GEO)
that contained breast cancer patient samples hybridized onto an exon array. We
downloaded the GSE33692 dataset that contained patient samples from three normal
breast samples, nine ductal carcinoma in situ (DCIS), and 10 invasive breast cancer
(IBC)52. Using GeneSpring GX, the differentially spliced genes between normal and
cancer samples (DCIS & IBC) were identified using cut off of Benjamini Hochberg FDR
of 0.05 and splice index above 0.5. There are 8223 genes between normal and IDC and
7570 genes between normal and DCIS to be differentially spliced. Subsequently, the
statistically significant spliced genes from our RNA-sequencing studies were overlapped
with the results from the microarray analysis. Since the samples in the microarray
couldn’t be classified into specific subtypes, all the differentially splicing genes discovered
in our RNA sequencing study (i.e. NBS vs. TNBC, Non-TNBC and HER2-positive)
were compared with the microarray compassion. There are 468 genes overlapping
between normal vs. IBC from microarray studies and RNA-sequencing studies.
Similarly, we found 434 genes overlapping form normal vs. DCIS comparison with
RNA-sequencing data. Additionally, we also compared subtype specific data from RNAseq studies with microarray results. Comparison of normal vs. IDC gave 213, 145 and
260 overlapping genes for TNBC, non-TNBC, HER-2 comparisons respectively.
Similarly, comparison of normal vs. DCIS gave 195, 135 and 238 genes for TNBC,
non-TNBC and HER-2 comparisons respectively.
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